189,152 Gilead Sciences, Inc. $GILD Shares Purchased by Bank Julius Baer & Co. Ltd Zurich

Key Points

• Bank Julius Baer increased its Gilead Sciences position by 22.3% in the third quarter, purchasing 189,152 additional shares and bringing its holdings to 1.04 million shares valued at approximately $155.2 million. Institutional investors own 83.67% of Gilead’s stock.
• Gilead reported stronger-than-expected quarterly results, with earnings of $2.55 per share and revenue of $8.30 billion, up 6.8% year over year. The company declared a quarterly dividend of $0.82 per share, equivalent to an annualized yield of about 1.9%.
• Analyst sentiment is broadly positive, with Gilead holding a “Moderate Buy” consensus rating and a $169.19 average price target, though investors face longer-term risks from potential Medicare-driven Biktarvy price cuts and the stock’s demanding valuation.

Bank Julius Baer & Co. Ltd Zurich increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 22.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,038,316 shares of the biopharmaceutical company's stock after buying an additional 189,152 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich owned 0.08% of Gilead Sciences worth $155,188,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Virtue Capital Management LLC increased its holdings in shares of Gilead Sciences by 12.8% during the third quarter. Virtue Capital Management LLC now owns 3,151 shares of the biopharmaceutical company's stock valued at $470,000 after acquiring an additional 357 shares in the last quarter. Greenleaf Trust raised its holdings in Gilead Sciences by 0.6% in the 3rd quarter. Greenleaf Trust now owns 24,345 shares of the biopharmaceutical company's stock valued at $3,629,000 after acquiring an additional 157 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. acquired a new stake in Gilead Sciences during the 3rd quarter valued at approximately $220,000. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Gilead Sciences by 0.3% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,972,668 shares of the biopharmaceutical company's stock valued at $443,076,000 after purchasing an additional 10,020 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Gilead Sciences in the third quarter worth $156,539,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

GILD opened at $170.68 on Monday. Gilead Sciences, Inc. has a 1-year low of $114.02 and a 1-year high of $175.65. The company has a market capitalization of $211.63 billion, a price-to-earnings ratio of -54.01 and a beta of 0.35. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.32 and a quick ratio of 0.95. The business has a 50 day moving average price of $150.87 and a two-hundred day moving average price of $139.79.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts' consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same quarter in the previous year, the firm earned $2.47 earnings per share. The business's revenue was up 6.8% on a year-over-year basis. Research analysts predict that Gilead Sciences, Inc. will post -1.03 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences's dividend payout ratio (DPR) is currently -103.80%.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the sale, the insider directly owned 113,684 shares in the company, valued at $17,759,714.48. This represents a 2.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O'Day sold 15,000 shares of the company's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $147.90, for a total value of $2,218,500.00. Following the completion of the transaction, the chief executive officer directly owned 566,683 shares of the company's stock, valued at $83,812,415.70. The trade was a 2.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 96,000 shares of company stock valued at $13,923,210 over the last quarter. 0.30% of the stock is owned by company insiders.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GILD shares. BMO Capital Markets reiterated an "outperform" rating and set a $184.00 price objective on shares of Gilead Sciences in a report on Friday. Jefferies Financial Group reissued a "buy" rating and set a $185.00 price target on shares of Gilead Sciences in a research report on Friday, October 23rd. HSBC lifted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, September 10th. Citigroup raised their price objective on shares of Gilead Sciences from $165.00 to $188.00 and gave the stock a "buy" rating in a research note on Friday. Finally, Barclays dropped their price target on Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 29th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $169.19.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.